James Shore, MSc

James Shore, MSc, is a technical product manager at The Native Antigen Company (now part of LGC Clinical Diagnostics), a manufacturer of antigens and antibodies for infectious diseases. After studying biochemistry at the University of Sheffield, James joined The Native Antigen Company where he is now responsible for developing the infectious disease portfolio. James was involved in the company’s development of the world’s first commercially available SARS-CoV-2 antigens in early 2020, and continues to support the development of unique antigens and antibodies for a range of viral, bacterial, and protozoal diseases.